Several analysts have recently updated their ratings and price targets for DexCom (NASDAQ: DXCM):

  • 9/29/2017 – DexCom was downgraded by analysts at Raymond James Financial, Inc. from an “outperform” rating to a “mkt perform” rating.
  • 9/29/2017 – DexCom had its “buy” rating reaffirmed by analysts at Leerink Swann. They now have a $57.00 price target on the stock, down previously from $85.00.
  • 9/28/2017 – DexCom was downgraded by analysts at J P Morgan Chase & Co from an “overweight” rating to a “neutral” rating. They now have a $71.00 price target on the stock, down previously from $93.00.
  • 9/28/2017 – DexCom was downgraded by analysts at Citigroup Inc. from an “outperform” rating to a “market perform” rating.
  • 9/28/2017 – DexCom had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $91.00 price target on the stock.
  • 9/28/2017 – DexCom had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $76.00 price target on the stock, down previously from $85.00.
  • 9/28/2017 – DexCom had its “market perform” rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $49.50 price target on the stock, down previously from $76.00.
  • 9/28/2017 – DexCom had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $69.00 price target on the stock, down previously from $90.00.
  • 9/28/2017 – DexCom had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $62.00 price target on the stock, down previously from $90.00.
  • 9/28/2017 – DexCom had its price target lowered by analysts at Cowen and Company from $90.00 to $64.00. They now have an “outperform” rating on the stock.
  • 9/28/2017 – DexCom was downgraded by analysts at Northland Securities from an “outperform” rating to a “market perform” rating. They now have a $60.00 price target on the stock, down previously from $85.00.
  • 9/28/2017 – DexCom had its price target lowered by analysts at Robert W. Baird from $79.00 to $58.00. They now have a “neutral” rating on the stock.
  • 9/28/2017 – DexCom had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $92.00 to $85.00. They now have an “outperform” rating on the stock.
  • 9/28/2017 – DexCom had its “equal weight” rating reaffirmed by analysts at Barclays PLC. They now have a $60.00 price target on the stock, down previously from $76.00.
  • 9/28/2017 – DexCom had its “buy” rating reaffirmed by analysts at Stephens. They now have a $70.00 price target on the stock, down previously from $83.00.
  • 9/28/2017 – DexCom had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $87.00 price target on the stock.
  • 9/28/2017 – DexCom was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 9/26/2017 – DexCom is now covered by analysts at Northland Securities. They set an “outperform” rating and a $85.00 price target on the stock.
  • 9/15/2017 – DexCom is now covered by analysts at Barclays PLC. They set an “equal weight” rating and a $76.00 price target on the stock.
  • 9/10/2017 – DexCom had its “hold” rating reaffirmed by analysts at Robert W. Baird. They now have a $79.00 price target on the stock.
  • 9/8/2017 – DexCom had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $87.00 price target on the stock.
  • 9/8/2017 – DexCom had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $90.00 price target on the stock.
  • 9/1/2017 – DexCom was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 8/22/2017 – DexCom had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $90.00 price target on the stock.
  • 8/19/2017 – DexCom was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/16/2017 – DexCom had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $78.00 price target on the stock, down previously from $87.00.
  • 8/14/2017 – DexCom was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “DexCom reported narrower-than-expected loss in the second quarter. We believe the company’s margins will continue to be under pressure in the coming quarters, owing to high product development costs and rising expenditures on research & development. Specifically, the company is expected to have lower margins on transmitter sales (in spite of the cost reduction initiatives). Additionally, cutthroat competition in the market for blood glucose monitoring devices is a major headwind. In the past one year, DexCom has underperformed the broader industry in terms of price. On the positive side, the glucose monitoring market represents significant commercial opportunity for DexCom. The company has also signed collaborative agreements with several companies, which should not only bring in cash, but also help expand its product portfolio.”
  • 8/9/2017 – DexCom was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 8/8/2017 – DexCom had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $90.00 price target on the stock, down previously from $105.00.

Shares of DexCom, Inc. (DXCM) opened at 47.18 on Wednesday. The stock’s market capitalization is $4.08 billion. The firm’s 50-day moving average is $69.77 and its 200-day moving average is $72.60. DexCom, Inc. has a one year low of $42.62 and a one year high of $88.80.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. The firm had revenue of $170.60 million during the quarter, compared to analyst estimates of $166.54 million. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. DexCom’s revenue for the quarter was up 24.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.24) EPS. Equities research analysts forecast that DexCom, Inc. will post ($0.80) EPS for the current year.

In other news, EVP Andrew K. Balo sold 3,200 shares of the stock in a transaction that occurred on Monday, July 10th. The shares were sold at an average price of $71.55, for a total value of $228,960.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin R. Sayer sold 6,000 shares of the stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $71.86, for a total transaction of $431,160.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,223 shares of company stock worth $2,285,138. Insiders own 1.70% of the company’s stock.

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Receive News & Ratings for DexCom Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc and related companies with MarketBeat.com's FREE daily email newsletter.